Scalper1 News
Merck’s (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three phases of clinical trials were finished, due to its “breakthrough therapy” designation. It’s a monoclonal antibody that attacks the mechanism that lets cancer cells fool the immune system into thinking Scalper1 News
Scalper1 News